Atenção: Todas as denúncias são sigilosas e sua identidade será preservada.
Os campos nome e e-mail são de preenchimento opcional
Metadados | Descrição | Idioma |
---|---|---|
Autor(es): dc.contributor | University of Portsmouth | - |
Autor(es): dc.contributor | Universidade de São Paulo (USP) | - |
Autor(es): dc.contributor | Universidad CEU Cardenal Herrera | - |
Autor(es): dc.contributor | Universidad Complutense de Madrid | - |
Autor(es): dc.contributor | Universidade Estadual Paulista (Unesp) | - |
Autor(es): dc.contributor | University Complutense de Madrid | - |
Autor(es): dc.creator | Lalatsa, Aikaterini | - |
Autor(es): dc.creator | Statts, Larry | - |
Autor(es): dc.creator | Adriana de Jesus, Jéssica | - |
Autor(es): dc.creator | Adewusi, Olivia | - |
Autor(es): dc.creator | Auxiliadora Dea-Ayuela, Maria | - |
Autor(es): dc.creator | Bolas-Fernandez, Francisco | - |
Autor(es): dc.creator | Dalastra Laurenti, Marcia | - |
Autor(es): dc.creator | Felipe Domingues Passero, Luiz [UNESP] | - |
Autor(es): dc.creator | Serrano, Dolores R. [UNESP] | - |
Data de aceite: dc.date.accessioned | 2022-02-22T00:32:45Z | - |
Data de disponibilização: dc.date.available | 2022-02-22T00:32:45Z | - |
Data de envio: dc.date.issued | 2020-12-11 | - |
Data de envio: dc.date.issued | 2020-12-11 | - |
Data de envio: dc.date.issued | 2020-10-15 | - |
Fonte completa do material: dc.identifier | http://dx.doi.org/10.1016/j.ijpharm.2020.119734 | - |
Fonte completa do material: dc.identifier | http://hdl.handle.net/11449/201153 | - |
Fonte: dc.identifier.uri | http://educapes.capes.gov.br/handle/11449/201153 | - |
Descrição: dc.description | Leishmaniasis is a neglected disease presenting cutaneous, mucosal and visceral forms and affecting an estimated 12 million mostly low-income people. Treatment of cutaneous leishmaniasis (CL) is recommended to expedite healing, reduce risk of scarring, prevent parasite dissemination to other mucocutaneous (common with New World species) or visceral forms and reduce the chance of relapse, but remains an unmet need. Available treatments are painful, prolonged (>20 days) and require hospitalisation, which increases the cost of therapy. Here we present the development of optimised topical self-nanoemulsifying drug delivery systems (SNEDDS) loaded with buparvaquone (BPQ, a hydroxynapthoquinone from the open Malaria Box) for the treatment of CL from New World species. The administration of topical BPQ-SNEDDS gels for 7 days resulted in a reduction of parasite load of 99.989 ± 0.019% similar to the decrease achieved with intralesionally administered Glucantime® (99.873 ± 0.204%) in a L. amazonensis BALB/c model. In vivo efficacy was supported by ex vivo permeability and in vivo tape stripping studies. BPQ-SNEDDS and their hydrogels demonstrated linear flux across non-infected CD-1 mouse skin ex vivo of 182.4 ± 63.0 μg cm−2 h−1 and 57.6 ± 10.8 μg cm−2 h−1 respectively localising BPQ within the skin in clinically effective concentrations (227.0 ± 45.9 μg and 103.8 ± 33.8 μg) respectively. These levels are therapeutic as BPQ-SNEDDS and their gels showed nanomolar in vitro efficacy against L. amazonensis and L. braziliensis amastigotes with excellent selectivity index toward parasites versus murine macrophages. In vivo tape stripping experiments indicated localisation of BPQ within the stratum corneum and dermis. Histology studies confirmed the reduction of parasitism and indicated healing in animals treated with BPQ-SNEDDS hydrogels. These results highlight the potential clinical capability of nano-enabled BPQ hydrogels towards a non-invasive treatment for CL. | - |
Descrição: dc.description | Biomaterials Bio-engineering and Nanomedicines (BioN) Laboratory Institute of Biomedical and Biomolecular Sciences School of Pharmacy and Biomedical Sciences University of Portsmouth, White Swan Road | - |
Descrição: dc.description | Laboratory of Pathology of Infectious Diseases (LIM-50) Medical School University of São Paulo, Avenida Dr. Arnaldo 455, 01246903 Cerqueira César | - |
Descrição: dc.description | Departamento de Farmacia Facultad de Ciencias de la Salud Universidad CEU Cardenal Herrera, Edificio Seminario s/n, 46113-Moncada | - |
Descrição: dc.description | Departament of Microbiology and Parasitology School of Pharmacy Universidad Complutense de Madrid, Plaza Ramón y Cajal s/n | - |
Descrição: dc.description | Institute of Biosciences São Paulo State University (UNESP) Praça Infante Dom Henrique s/n | - |
Descrição: dc.description | Institute for Advanced Studies of Ocean Biosciences São Paulo State University (UNESP), Av. João Francisco Bensdorp, 1178 | - |
Descrição: dc.description | Departament of Pharmaceutics and Food Technology and Instituto Universitario de Farmacia Industrial (IUFI) School of Pharmacy University Complutense de Madrid, Plaza Ramón y Cajal s/n | - |
Descrição: dc.description | Institute of Biosciences São Paulo State University (UNESP) Praça Infante Dom Henrique s/n | - |
Descrição: dc.description | Institute for Advanced Studies of Ocean Biosciences São Paulo State University (UNESP), Av. João Francisco Bensdorp, 1178 | - |
Idioma: dc.language | en | - |
Relação: dc.relation | International Journal of Pharmaceutics | - |
???dc.source???: dc.source | Scopus | - |
Palavras-chave: dc.subject | Buparvaquone | - |
Palavras-chave: dc.subject | Cutaneous Leishmaniasis | - |
Palavras-chave: dc.subject | Franz cell diffusion assays | - |
Palavras-chave: dc.subject | Hydrogels | - |
Palavras-chave: dc.subject | Mucocutaneous Leishmaniasis | - |
Palavras-chave: dc.subject | Self-nanoemulsifying drug delivery systems (SNEDDS) | - |
Palavras-chave: dc.subject | Tape stripping | - |
Título: dc.title | Topical buparvaquone nano-enabled hydrogels for cutaneous leishmaniasis | - |
Tipo de arquivo: dc.type | livro digital | - |
Aparece nas coleções: | Repositório Institucional - Unesp |
O Portal eduCAPES é oferecido ao usuário, condicionado à aceitação dos termos, condições e avisos contidos aqui e sem modificações. A CAPES poderá modificar o conteúdo ou formato deste site ou acabar com a sua operação ou suas ferramentas a seu critério único e sem aviso prévio. Ao acessar este portal, você, usuário pessoa física ou jurídica, se declara compreender e aceitar as condições aqui estabelecidas, da seguinte forma: